Purple Biotech PPBT, a clinical-stage oncology company, reported positive final results from the mid-stage study of its lead candidate, CM24, for treating pancreatic ductal adenocarcinoma (“PDAC”) ...
On Monday, Purple Biotech Ltd (NASDAQ:PPBT) reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in ...
Theriva Biologics stock rose on Monday as it received positive Scientific Advice from CHMP for a Phase 3 trial of VCN-01 for ...
Daraxonrasib received FDA breakthrough therapy designation for metastatic PDAC with KRAS G12 mutations, expediting its development. The designation is based on promising phase 1 trial results, with ...
Sirios announces that its Board of Directors has granted 100,000 stock options to its Chief Financial Officer and Secretary under its Stock Option Incentive Plan. The options have an exercise price of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback